These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 8608343)
21. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model. Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700 [TBL] [Abstract][Full Text] [Related]
22. Protein C inhibitor is expressed in keratinocytes of human skin. Krebs M; Uhrin P; Vales A; Prendes-Garcia MJ; Wojta J; Geiger M; Binder BR J Invest Dermatol; 1999 Jul; 113(1):32-7. PubMed ID: 10417615 [TBL] [Abstract][Full Text] [Related]
23. Simultaneous stimulation of urokinase and tissue-type plasminogen activators by phorbol esters in human ovarian carcinoma cells. Band V; Karlan BY; Zurawski VR; Littlefield BA J Cell Physiol; 1989 Jan; 138(1):106-14. PubMed ID: 2492025 [TBL] [Abstract][Full Text] [Related]
24. Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice. Lund LR; Green KA; Stoop AA; Ploug M; Almholt K; Lilla J; Nielsen BS; Christensen IJ; Craik CS; Werb Z; Danø K; Rømer J EMBO J; 2006 Jun; 25(12):2686-97. PubMed ID: 16763560 [TBL] [Abstract][Full Text] [Related]
25. Tissue plasminogen activator and urokinase plasminogen activator in human epileptogenic pathologies. Iyer AM; Zurolo E; Boer K; Baayen JC; Giangaspero F; Arcella A; Di Gennaro GC; Esposito V; Spliet WG; van Rijen PC; Troost D; Gorter JA; Aronica E Neuroscience; 2010 May; 167(3):929-45. PubMed ID: 20219643 [TBL] [Abstract][Full Text] [Related]
26. Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines. Lyon PB; See WA; Xu Y; Cohen MB Prostate; 1995 Oct; 27(4):179-86. PubMed ID: 7479384 [TBL] [Abstract][Full Text] [Related]
27. Expression of plasminogen activator and inhibitor, urokinase receptor and inhibin subunits in rhesus monkey testes. Zhang T; Zhou HM; Liu YX Mol Hum Reprod; 1997 Mar; 3(3):223-31. PubMed ID: 9237248 [TBL] [Abstract][Full Text] [Related]
28. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis. Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903 [TBL] [Abstract][Full Text] [Related]
29. mRNA for tissue-type plasminogen activator is present in lesional epidermis from patients with psoriasis, pemphigus, or bullous pemphigoid, but is not detected in normal epidermis. Baird J; Lazarus GS; Belin D; Vassalli JD; Busso N; Gubler P; Jensen PJ J Invest Dermatol; 1990 Nov; 95(5):548-52. PubMed ID: 2121833 [TBL] [Abstract][Full Text] [Related]
30. Biological mechanisms underlying the clinical effects of RU 486: modulation of cultured endometrial stromal cell plasminogen activator and plasminogen activator inhibitor expression. Lockwood CJ; Krikun G; Papp C; Aigner S; Schatz F J Clin Endocrinol Metab; 1995 Apr; 80(4):1100-5. PubMed ID: 7714076 [TBL] [Abstract][Full Text] [Related]
31. Tissue-type plasminogen activator mutants imitating urokinase in the peptide link between kringle and protease domains and at selected sites within the protease domain. Hinzmann B; Wernicke D; Pfeifer M; Zacharias U; Fischer B; Eisenmenger F; Will H Eur J Biochem; 1993 Apr; 213(1):437-43. PubMed ID: 8386628 [TBL] [Abstract][Full Text] [Related]
32. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Bugge TH; Flick MJ; Danton MJ; Daugherty CC; Romer J; Dano K; Carmeliet P; Collen D; Degen JL Proc Natl Acad Sci U S A; 1996 Jun; 93(12):5899-904. PubMed ID: 8650190 [TBL] [Abstract][Full Text] [Related]
34. Elevations of tissue-type plasminogen activator and differential expression of urokinase-type plasminogen activator in diseased aorta. Shireman PK; McCarthy WJ; Pearce WH; Shively VP; Cipollone M; Kwaan HC J Vasc Surg; 1997 Jan; 25(1):157-64. PubMed ID: 9013920 [TBL] [Abstract][Full Text] [Related]
35. Protein kinase C mediates up-regulation of urokinase and its receptor in the migrating keratinocytes of wounded cultures, but urokinase is not required for movement across a substratum in vitro. Ando Y; Jensen PJ J Cell Physiol; 1996 Jun; 167(3):500-11. PubMed ID: 8655604 [TBL] [Abstract][Full Text] [Related]
36. Expression of avian urokinase and tissue-type plasminogen activator messenger ribonucleic acid during follicle development and atresia. Johnson AL; Bridgham JT; Anthony RV Biol Reprod; 1997 Mar; 56(3):581-8. PubMed ID: 9047000 [TBL] [Abstract][Full Text] [Related]
37. Differential expression of urokinase-type plasminogen activator (uPA), its receptor (uPA-R), and inhibitor type-2 (PAI-2) during differentiation of keratinocytes in an organotypic coculture system. Schaefer BM; Stark HJ; Fusenig NE; Todd RF; Kramer MD Exp Cell Res; 1995 Oct; 220(2):415-23. PubMed ID: 7556451 [TBL] [Abstract][Full Text] [Related]
38. A high-affinity receptor for urokinase plasminogen activator on human keratinocytes: characterization and potential modulation during migration. McNeill H; Jensen PJ Cell Regul; 1990 Oct; 1(11):843-52. PubMed ID: 1965151 [TBL] [Abstract][Full Text] [Related]
39. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration. Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795 [TBL] [Abstract][Full Text] [Related]